Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.32 |
| ▸ | WNT3A | P56704 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5707587 | 1.00 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3P2RX7HTT | |
| SCHEMBL2907033 | 1.00 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3P2RX7HTT | |
| SCHEMBL8960840 | 1.00 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3P2RX7HTT | |
| SCHEMBL3395341 | 0.87 | HTT (0.33) | SLC6A2SLC6A4SLC6A3P2RX7HTT | |
| SCHEMBL4750928 | 0.85 | SLC6A2 (0.31) | SLC6A2SLC6A4SLC6A3P2RX7HTT | |
| SCHEMBL4982728 | 0.84 | P2RX7 (0.32) | SLC6A2SLC6A4SLC6A3P2RX7HTT | |
| SCHEMBL5707632 | 0.84 | P2RX7 (0.32) | SLC6A2SLC6A4SLC6A3P2RX7HTT | |
| SCHEMBL5707571 | 0.84 | P2RX7 (0.32) | SLC6A2SLC6A4SLC6A3P2RX7HTT | |
| SCHEMBL4411815 | 0.79 | CTNNB1 (0.32) | P2RX7HTTCTNNB1WNT3AALDH1A1 | |
| SCHEMBL4986617 | 0.79 | NPC1 (0.33) | SLC6A2SLC6A4SLC6A3P2RX7HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6764829-B2 | DETECTING PARASITES USING CHROMOGENIC SUBSTRATES; OBTAIN SAMPLE, INCUBATE WITH CHROMGENIC SUBSTRATE, DETECT FORMATION OF CHROMOPHORE PRODUCT | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2004-07-20 | — | — | US | disclosed |
| EP-1418179-A2 | Compositions and methods for detecting and modulating rna activity and gene expression | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20020132263-A1 | Enzyme detection/assay method and substrates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-19 | — | — | US | disclosed |
| US-6379911-B2 | ANALYZING NUCLEOSIDE HYDROLASES; DETECTING PARASITES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2002-04-30 | — | — | US | disclosed |
| US-20010019823-A1 | ENZYME DETECTION/ASSAY METHOD AND SUBSTRATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-09-06 | — | — | US | disclosed |
| US-6262241-B1 | ANTISENSE COMPOUNDS WHICH CLEAVE PHOSPHORODIESTER BONDS AND IMPROVE PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES OF OLIGONUCLEOTIDES, USEFUL IN DIAGNOSING DISEASES | ISIS PHARMACEUTICALS, INC. | 2001-07-17 | — | — | US | disclosed |
| EP-0604409-A4 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION. | ISIS PHARMACEUTICALS INC (US) | 1996-06-12 | — | — | EP | disclosed |
| EP-0604409-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1994-07-06 | — | — | EP | disclosed |
| WO-1991010671-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1991-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010019823-A1 | ENZYME DETECTION/ASSAY METHOD AND SUBSTRATES | PNP, TREH, XDH | SLC6A2 1387/4885SLC6A4 2161/4885SLC6A3 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.